

TIME	SUBJECT																		
10:30hrs ~ 11:30hrs	<p>MERCK-PFIZER ALLIANCE RENAL SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</p> <p>Symposium title: What have we learnt from treating first-line aRCC patients with BAVENCIO® ▼ (avelumab) and axitinib? <i>BAVENCIO® in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (aRCC)</i> <i>For BAVENCIO® (avelumab) + axitinib prescribing information and adverse event reporting information, please click here.</i></p> <p>In this highly interactive symposium, chaired by Dr Sarah Rudman, the faculty will provide an overview of the current first-line aRCC landscape, with a particular focus on IO–TKI combinations. The speakers will then present real-world patient cases that illustrate key considerations in clinical practice. The meeting will conclude with an interactive session in which the panel will discuss and respond to questions from the audience. We look forward to welcoming you to this virtual symposium, organised and funded by Pfizer on behalf of the Merck–Pfizer Alliance.</p> <table border="0" data-bbox="362 678 2123 1029"> <tr> <td data-bbox="362 678 622 710">10:30hrs ~ 10:35hrs</td> <td data-bbox="631 678 1444 710">Welcome and introduction</td> <td data-bbox="1453 678 2123 710"><i>Dr Sarah Rudman</i></td> </tr> <tr> <td data-bbox="362 718 622 750">10:35hrs ~ 10:50hrs</td> <td data-bbox="631 718 1444 798">Overview of the current first-line aRCC landscape with a focus on IO-TKI combinations</td> <td data-bbox="1453 718 2123 750"><i>Dr Enrique Grande</i></td> </tr> <tr> <td data-bbox="362 805 622 837">10:50hrs ~ 11:00hrs</td> <td data-bbox="631 805 1444 885">A patient case study with Dr Sarah Rudman and Dr Stam Kapetanakis</td> <td data-bbox="1453 805 2123 837"><i>Dr Sarah Rudman & Dr Stam Kapetanakis</i></td> </tr> <tr> <td data-bbox="362 893 622 925">11:00hrs ~ 11:10hrs</td> <td data-bbox="631 893 1444 925">A patient case study with Professor Amit Bahl</td> <td data-bbox="1453 893 2123 925"><i>Professor Amit Bahl</i></td> </tr> <tr> <td data-bbox="362 933 622 965">11:10hrs ~ 11:25hrs</td> <td data-bbox="631 933 1444 965">Panel discussion and Q&A</td> <td data-bbox="1453 933 2123 965"><i>All faculty</i></td> </tr> <tr> <td data-bbox="362 973 622 1005">11:25hrs ~ 11:30hrs</td> <td data-bbox="631 973 1444 1005">Conclusions and key learnings</td> <td data-bbox="1453 973 2123 1005"><i>Dr Sarah Rudman</i></td> </tr> </table> <p>aRCC, advanced renal cell carcinoma; IO, immuno-oncology; TKI, tyrosine kinase inhibitor This promotional virtual meeting is organised and funded by Pfizer Ltd on behalf of Merck-Pfizer Alliance; product related information will be discussed PP-BAV-GBR-1090. Date of Preparation: September 2021</p>	10:30hrs ~ 10:35hrs	Welcome and introduction	<i>Dr Sarah Rudman</i>	10:35hrs ~ 10:50hrs	Overview of the current first-line aRCC landscape with a focus on IO-TKI combinations	<i>Dr Enrique Grande</i>	10:50hrs ~ 11:00hrs	A patient case study with Dr Sarah Rudman and Dr Stam Kapetanakis	<i>Dr Sarah Rudman & Dr Stam Kapetanakis</i>	11:00hrs ~ 11:10hrs	A patient case study with Professor Amit Bahl	<i>Professor Amit Bahl</i>	11:10hrs ~ 11:25hrs	Panel discussion and Q&A	<i>All faculty</i>	11:25hrs ~ 11:30hrs	Conclusions and key learnings	<i>Dr Sarah Rudman</i>
10:30hrs ~ 10:35hrs	Welcome and introduction	<i>Dr Sarah Rudman</i>																	
10:35hrs ~ 10:50hrs	Overview of the current first-line aRCC landscape with a focus on IO-TKI combinations	<i>Dr Enrique Grande</i>																	
10:50hrs ~ 11:00hrs	A patient case study with Dr Sarah Rudman and Dr Stam Kapetanakis	<i>Dr Sarah Rudman & Dr Stam Kapetanakis</i>																	
11:00hrs ~ 11:10hrs	A patient case study with Professor Amit Bahl	<i>Professor Amit Bahl</i>																	
11:10hrs ~ 11:25hrs	Panel discussion and Q&A	<i>All faculty</i>																	
11:25hrs ~ 11:30hrs	Conclusions and key learnings	<i>Dr Sarah Rudman</i>																	